Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chandler Park

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Expert Review of Endocrinology & Metabolism|February 10, 2019
Sorafenib and thyroid cancerChandler Park, Jessica Perini, Roger W Farmer, et al.
Clinical Hematology International|August 11, 2025
Beyond Hypomethylating Agents: Novel Therapies and Targeted ApproachesViviana Cortiana, Harshitha Vallabhaneni, Jenna Ghazal, et al.
Biomedicines|February 27, 2026
Evolving Therapeutic Algorithms in Chronic Myeloid Leukemia: Integrating Efficacy, Safety, and SurvivorshipYan Leyfman, Ahmed Hashim Azeez, Taha Kassim Dohadwala, et al.
Future Oncology (London, England)|September 1, 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapyPetros Grivas, Scott T Tagawa, Rohit K Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyDaniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Expert Review of Endocrinology & Metabolism|February 10, 2019
Sorafenib and thyroid cancerChandler Park, Jessica Perini, Roger W Farmer, et al.
Clinical Hematology International|August 11, 2025
Beyond Hypomethylating Agents: Novel Therapies and Targeted ApproachesViviana Cortiana, Harshitha Vallabhaneni, Jenna Ghazal, et al.
Biomedicines|February 27, 2026
Evolving Therapeutic Algorithms in Chronic Myeloid Leukemia: Integrating Efficacy, Safety, and SurvivorshipYan Leyfman, Ahmed Hashim Azeez, Taha Kassim Dohadwala, et al.
Future Oncology (London, England)|September 1, 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapyPetros Grivas, Scott T Tagawa, Rohit K Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyDaniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
Pageof 1